All In Biotech

Drug Trial Radar · NCT07300956

Treating Young Children With Attention Deficit Hyperactivity Disorder

Comparing Medication Treatments for Neurodevelopmental Differences in Young Children on Rates of Beneficial Response

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

370

Planned (sponsor's estimate)

Start

Feb 16, 2026

Primary completion

Feb 2030

Study completion Jul 2030

Sponsor

Lead sponsor
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; Children's Hospital of Philadelphia; Developmental Behavioral Pediatrics Research Network; Boston Children's Hospital, Boston, MA, USA; Children's Mercy Hospital Kansas City; Stanford University
First posted
Dec 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project will evaluate the effectiveness of Methylphenidate versus Guanfacine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 3 through 5 years (inclusive), as measured by clinician rating of global improvement.

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

  • Guanfacine (GUA)Drug

    After engaging in behavioral therapy, participants randomized into this group participants will be prescribed Guanfacine. Each child's prescribing clinician determines the form and dose of guanfacine that the child receives. Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release

  • Methylphenidate (MPH)Drug

    Participants randomized into this group will be prescribed Methylphenidate. Each child's prescribing clinician determines the form and dose of methylphenidate that the child receives. Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Relexxii, Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid), methylphenidate hydrochloride- extended release, methylphenidate hydrochloride- immediate release

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Global Impression-ImprovementTime frame: From enrollment to the end of the 16-week medication treatment.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Medicine Children's Health

    Palo Alto, California · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Children's Mercy Hospital

    Kansas City, Missouri · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.